The bispecific boom: Genentech pays $120M to tie the knot with Xencor on an IL-15 alliance
Genentech is fronting $120 million to partner up with Xencor $XNCR on its IL-15 cytokine work, nabbing co-development rights to the late preclinical drug XmAb24306 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
